Best Oligonucleotide / ASO CDMOs in Asia
· updated as new inspection, certificate, and trial data enters the platform
6
CDMOs tracked
6
Fully scored
1
With FDA records
2
FDA inspections
5
EMA/MHRA GMP certs
Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.
Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 0 NAI (no action), 1 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (2), Czechia (2), Germany (1), Ireland (1), UNITED STATES (1).
Last updated 2026-09-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 2 |
SP
ST Pharm
Seoul, South Korea
|
73.2 | 89.4 | 2 insp · 4 GMP | — | 0 programs |
| 3 |
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
|
63.0 | — | — | — | 0 programs |
| 4 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 5 |
RR
RiboBio
Guangzhou, China
|
59.0 | — | — | — | 0 programs |
| 6 |
HB
Hongene Biotech
Singapore (primary operations: Union City, CA / Shanghai, China)
|
56.5 | — | — | — | 0 programs |
What to evaluate in a Oligonucleotide / ASO CDMO
Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Oligonucleotide / ASO CDMOs — Frequently Asked Questions
Who are the top Oligonucleotide / ASO CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Oligonucleotide / ASO CDMOs include Ajinomoto Bio-Pharma Services, ST Pharm, Sumitomo Chemical Advanced Medical. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Oligonucleotide / ASO CDMOs have FDA inspection records?
CDMO Signal tracks 1 Oligonucleotide / ASO CDMO with FDA inspection records and 5 EMA/MHRA GMP certificates across the group.
What should I look for in an oligonucleotide CDMO?
Match synthesis scale to your demand, confirm experience with your backbone chemistry and any conjugation (e.g. GalNAc), prioritize strong purity analytics, and a clean FDA and EMA/MHRA record.
What therapeutics do oligonucleotide CDMOs make?
Antisense oligonucleotides (ASOs), siRNAs, aptamers, and related nucleic-acid drugs — increasingly with conjugation chemistries like GalNAc for targeted delivery.
Related modalities